Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2016 05:01 ET | Source: Affimed N.V.

Affimed Presents Data on EGFRwt and EGFRvIII-targeting NK- and T-Cell TandAbs at the AACR Annual Meeting 2016

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, April 21, 2016 - Affimed...
April 21, 2016 05:00 ET | Source: Affimed N.V.

Affimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 2016

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, April 21, 2016 - Affimed...
March 30, 2016 07:30 ET | Source: Affimed N.V.

Affimed Reports Financial Results for Fourth Quarter and Year End 2015

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} --Successful Financings Closed and US...
March 23, 2016 06:01 ET | Source: Affimed N.V.

Affimed Announces Fourth Quarter and Year End 2015 Financial Results and Corporate Update Conference Call

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, March 23, 2016 -...
March 17, 2016 06:00 ET | Source: Affimed N.V.

Affimed to Present Data on NK- and T-Cell Engagers at the AACR Annual Meeting 2016

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} --AFM13/anti-PD-1 combination induces...
February 29, 2016 05:01 ET | Source: Affimed N.V.

Affimed to Present at the Cowen and Company 36th Annual Health Care Conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, February 29, 2016 -...
February 22, 2016 05:00 ET | Source: Affimed N.V.

Affimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, February 22, 2016 -...
February 04, 2016 05:01 ET | Source: Affimed N.V.

Affimed to Present at the Leerink Partners 5th Annual Global Healthcare Conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, February 4, 2016...
January 25, 2016 05:00 ET | Source: Affimed N.V.

Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Hodgkin Lymphoma

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, January 25, 2016 -...
January 21, 2016 10:00 ET | Source: Affimed N.V.

Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, January 21, 2016 -...